Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts, and prostate cell lines

ABSTRACT: Chromatin accessibility profiling analsis was performed in 22 human prostate cancer organoid, 6 Xenografts and 7 cell lines

ORGANISM(S): Homo sapiens

PROVIDER: GSE193917 | GEO | 2022/01/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts

Project description:Transcriptome profiling analysis was performed in 22 human prostate cancer organoids, 6 patient-derived xenografts (PDXs) and 7 cell lines.

2021-08-04 | GSE181374 | GEO

RNA-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts

Project description:RNA-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts

| PRJNA751853 | ENA

ATAC-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts, and prostate cell lines

Project description:ATAC-Seq of MSK-PCa series of Patient Derived Organoids and Xenografts, and prostate cell lines

| PRJNA798395 | ENA

DNA methylation analysis of breast cancer patient-derived xenografts and organoids

Project description:To understand if the generation of xenograft and organoid models of breast cancer alters DNA methylation, we compared the genome-wide methylation profile of matching patient tumors, patient derived xenografts, and organoid cultures derived from xenografts.

2022-01-09 | GSE186747 | GEO

Proteomics of prostate cancer patient derived xenografts

Project description:A set of 17 prostate cancer patient-derived xenografts (PDX, Lin et al 2014, Cancer research) was analyzed by mass spectrometry-based proteomics to characterize the effects of castration in vivo, and the proteome differences between NEPC and prostate adenocarcinomas.

2019-09-11 | PXD009636 | Pride

Patient-derived xenografts and organoids model therapy response in prostate cancer.

Project description:Therapy resistance and metastatic processes in prostate cancer (PCa) remain undefined, due to lack of experimental models that mimic different disease stages. We describe an androgen-dependent PCa patient-derived xenograft (PDX) model from treatment-naïve, soft tissue metastasis (PNPCa). RNA and whole-exome sequencing of the PDX tissue and organoids confirmed transcriptomic and genomic similarity to primary tumor. PNPCa harbors BRCA2 and CHD1 somatic mutations, shows an SPOP/FOXA1-like transcriptomic signature and microsatellite instability, which occurs in 3% of advanced PCa and has never been modeled in vivo. Comparison of the treatment-naïve PNPCa with additional metastatic PDXs (BM18, LAPC9), in a medium-throughput organoid screen of FDA-approved compounds, revealed differential drug sensitivities. Multikinase inhibitors (ponatinib, sunitinib, sorafenib) were broadly effective on all PDX- and patient-derived organoids from advanced cases with acquired resistance to standard-of-care compounds. This proof-of-principle study may provide a preclinical tool to screen drug responses to standard-of-care and newly identified, repurposed compounds.

| S-EPMC7892572 | biostudies-literature

Thoracic patient-derived xenografts

Project description:Thoracic patient-derived xenografts

| PRJNA339191 | ENA

RNA-Seq of MSK-PCa3 prostate cancer organoids upon knockdown of FOSL1, YAP, TAZ, or YAP/TAZ

Project description:Transcriptome analysis of prostate cancer patient derived organoid MKS-PCa3 upon knockdown of FOSL1, YAP, TAZ, or YAP/TAZ mediated by siRNAs

2022-02-20 | GSE196813 | GEO

Patient-derived Human Breast Cancer Xenografts

Project description:Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of SCID/Beige and NOD/SCID/IL2γ-receptor null (NSG) mice, under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (~23% and ~19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing unique 25 patients. Most tumors yielding xenografts were “triple-negative” (ER-PR-HER2+) (n=19). However, we established lines from three ER-PR-HER2+ tumors, one ER+PR-HER2-, one ER+PR+HER2- and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biological consistency with the tumor of origin, are phenotypic stability across multiple transplant generations at the histological, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses. Xenografts representing 12 patients, including two ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. The study was designed to determine how stable patient-derived xenografts are across multiple transplant generations in mice, and to determine how closely xenografts established with pre-treatment samples cluster with xenografts established with post-treatment samples. Overall, pre-treatment and post-treatment samples derived from the same patient cluster together, and multiple transplant generations of xenografts derived from an individual patient cluster together.

2013-05-30 | E-GEOD-46106 | biostudies-arrayexpress

Characterization of an abiraterone ultra-responsive phenotype in castration-resistant prostate cancer patient-derived xenografts

Project description:To identify the molecular signature associated with abiraterone acetate (AA) response and mechanisms underlying AA resistance in castration-resistant prostate cancer patient-derived xenografts (PDXs).

2016-12-22 | GSE85672 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data